Xeris Pharmaceuticals, Inc. (“Xeris”) (Nasdaq: XERS) and Strongbridge Biopharma plc (“Strongbridge”) (Nasdaq: SBBP) have entered into a definitive agreement under which Xeris will acquire Strongbridge for stock and contingent value rights. Together they will create a diversified biopharmaceutical company with an enhanced growth profile, well-positioned for long-term product development and commercial success.
Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma
Rule 2.5 Announcement
Events and Presentations
Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc Investor Conference Call
Xeris Pharmaceuticals SEC Filings
Strongbridge Biopharma SEC Filings